Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
33.21
-0.41 (-1.22%)
At close: Jun 26, 2026, 4:00 PM EDT
33.40
+0.19 (0.57%)
After-hours: Jun 26, 2026, 7:00 PM EDT
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 33,950 employees as of December 31, 2025. The number of employees decreased by 2,880 or -7.82% compared to the previous year.
Employees
33,950
Change (1Y)
-2,880
Growth (1Y)
-7.82%
Revenue / Employee
$511,016
Profits / Employee
$46,097
Market Cap
38.67B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33,950 | -2,880 | -7.82% |
| Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
| Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
| Dec 31, 2022 | 36,826 | -711 | -1.89% |
| Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
| Dec 31, 2020 | 40,216 | 177 | 0.44% |
| Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
| Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
| Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
| Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
| Dec 31, 2015 | 42,888 | -121 | -0.28% |
| Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
| Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
| Dec 31, 2012 | 45,948 | 194 | 0.42% |
| Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
| Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
| Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
| Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
| Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
| Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
| Dec 31, 2005 | 14,698 | 885 | 6.41% |
| Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
| Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
| Dec 31, 2002 | 9,577 | 591 | 6.58% |
| Dec 31, 2001 | 8,986 | 361 | 4.19% |
| Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
TEVA News
- 7 days ago - Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? - The Motley Fool
- 8 days ago - Teva Pharmaceutical Industries (TEVA) Seeks FDA Approval for Ecopipam in Tourette Syndrome - GuruFocus
- 8 days ago - TEVA Advances Pediatric Tourette Syndrome Treatment with New Drug Application - GuruFocus
- 8 days ago - Teva Pharmaceutical Industries Ltd (TEVA) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus
- 8 days ago - Teva submits NDA for Ecopipam to FDA - TheFly
- 8 days ago - Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome - GlobeNewsWire
- 8 days ago - Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET - GlobeNewsWire
- 8 days ago - Analyst Maintains Buy Rating on Teva (TEVA) Amid Recent Performance Concerns - GuruFocus